Conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors Journal Article


Authors: McHugh, D. J.; Feldman, D. R.
Article Title: Conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors
Abstract: The majority of metastatic germ cell tumors (GCTs) are cured with cisplatin-based chemotherapy, but 20-30% of patients will relapse after first-line chemotherapy and require additional salvage strategies. The two major salvage approaches in this scenario are high-dose chemotherapy (HDCT) with autologous stem cell transplant (ASCT) or conventional-dose chemotherapy (CDCT). Both CDCT and HDCT have curative potential in the management of relapsed/refractory GCT. However, due to a lack of conclusive randomized trials, it remains unknown whether sequential HDCT or CDCT represents the optimal initial salvage approach, with practice varying between tertiary institutions. This represents the most pressing question remaining for defining GCT treatment standards and optimizing outcomes. The authors review prognostic factors in the initial salvage setting as well as the major studies assessing the efficacy of CDCT, HDCT, or both, describing the strengths and weaknesses that formed the rationale behind the ongoing international phase III "TIGER" trial. © 2018 Deaglan J. McHugh and Darren R. Feldman.
Journal Title: Advances in Urology
Volume: 2018
ISSN: 1687-6369
Publisher: Hindawi Publishing Corporation  
Date Published: 2018-03-15
Start Page: 7272541
Language: English
DOI: 10.1155/2018/7272541
PROVIDER: scopus
PMCID: PMC5874975
PUBMED: 29736168
DOI/URL:
Notes: Review -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Darren Richard Feldman
    173 Feldman
  2. Deaglan Joseph McHugh
    4 McHugh